<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Junayd Alimohamed on Medium]]></title>
        <description><![CDATA[Stories by Junayd Alimohamed on Medium]]></description>
        <link>https://medium.com/@junayd.alimohamed?source=rss-d9ea5576040d------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*MiDZNM7pEW4Tege0</url>
            <title>Stories by Junayd Alimohamed on Medium</title>
            <link>https://medium.com/@junayd.alimohamed?source=rss-d9ea5576040d------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 05:52:11 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@junayd.alimohamed/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[How I Built Three CD19 CRISPR Plasmid Designs Using Benchling]]></title>
            <link>https://medium.com/@junayd.alimohamed/how-i-built-three-cd19-crispr-plasmid-designs-using-benchling-0d90cbf78908?source=rss-d9ea5576040d------2</link>
            <guid isPermaLink="false">https://medium.com/p/0d90cbf78908</guid>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[crispr-cas9]]></category>
            <category><![CDATA[cd19]]></category>
            <category><![CDATA[gene-editing]]></category>
            <dc:creator><![CDATA[Junayd Alimohamed]]></dc:creator>
            <pubDate>Sat, 31 Oct 2026 16:58:10 GMT</pubDate>
            <atom:updated>2026-10-31T16:59:11.046Z</atom:updated>
            <content:encoded><![CDATA[<h3>Overview</h3><p>I used Benchling (DNA design software) to create three digital plasmid designs for CRISPR (DNA editing), each with a different guide targeting <strong>CD19</strong>. Assembly 1 had lower reported scores than Assembly 2, while Assembly 3 targeted the <strong>coding region</strong> and had the lowest overall off-target score. Comparing them showed why the cut location matters alongside the scores; <em>no cells were edited or tested</em>.</p><h3>See the project</h3><p><a href="https://drive.google.com/file/d/1qS6HuTg-FxYgJbrGjMy48q47WXXdEb9u/view?usp=sharing">Movie on 2026-10-29 at 10.07 PM.mov</a></p><p><a href="https://benchling.com/s/seq-baMuh6wiwPCOqCCxeAP9?item_id=seq_wM8akxHb3C&amp;m=slm-KSyRTF5YlDj9kTkhQlm3">My Benchling CD19 design</a></p><h3>Why I chose CD19</h3><p>The CD19 gene codes for a protein found on the surface of B cells (immune cells), including some cancer cells. CD19 targeted CAR-T therapy uses modified immune cells to recognise this protein. Losing CD19 can help cancer cells escape that recognition.</p><p>I wanted to understand how CRISPR could help researchers study this loss. For this Build, I explored designs that might disrupt CD19, without testing them in cells or demonstrating a knockout (loss of gene function).</p><h3>What I recreated</h3><p>I adapted a CRISPR design tutorial from The Knowledge Society (TKS), a student innovation program. The tutorial uses BRCA2 (a DNA repair gene). I followed the same guide design and plasmid assembly workflow with CD19 to understand the steps and decisions involved. Since I changed the target gene, I was recreating the workflow rather than reproducing its results.</p><h3>Key terms</h3><ul><li><strong>Cas9:</strong> The protein that cuts DNA.</li><li><strong>Guide RNA (gRNA):</strong> RNA that helps Cas9 recognise a target DNA sequence.</li><li><strong>Plasmid:</strong> A DNA molecule carrying instructions for making Cas9 and the guide RNA in these designs.</li><li><strong>PAM:</strong> A short DNA sequence beside the target that Cas9 needs to recognise.</li><li><strong>CDS:</strong> The part of a gene’s transcript that codes for a protein.</li><li><strong>5′ UTR:</strong> The section of an RNA before the CDS; it can affect protein production.</li><li><strong>On-target score:</strong> A prediction used to compare guide activity at the intended site.</li><li><strong>Overall off-target score:</strong> A prediction used to compare guide specificity. Higher is better for the scores shown here.</li><li><strong>Oligos:</strong> Short pieces of DNA used here to build the guide insert.</li><li><strong>FWD (forward):</strong> The DNA oligo containing the guide sequence and cloning connectors.</li><li><strong>REV (reverse):</strong> The matching DNA oligo that pairs with FWD to form the insert.</li></ul><h3>How I built and compared the designs</h3><p>In Benchling, I used GRCh38/hg38, a human reference genome (standard DNA sequence for comparison), and the CD19–201 transcript (an RNA version of the gene). Each plasmid design has a different guide insert (DNA encoding the guide’s targeting sequence). I compared the guides’ target locations and predicted scores.</p><ol><li>I opened CD19 in Benchling and selected target regions to generate candidate guides.</li><li>I selected three guides and used Benchling’s assembly tool to create a separate plasmid design for each one</li><li>I recorded the forward and reverse oligos and the resulting plasmid maps.</li><li>I checked each guide’s cut position, strand, PAM and scores, then located the cut within the transcript.</li></ol><p>I compared computer predictions of activity and specificity (selectivity for the intended DNA site). These scores have no physical units and aren’t success percentages. Since this was a digital design project, I didn’t measure editing in cells or use experimental controls.</p><p>The * beside an on-target score means Benchling used the sequence only Doench/Fusi 2016 model, without the cut’s position in the CDS. I considered the scores alongside each guide’s cut location.</p><h3>Assembly 1</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vNvckS4bnAUG869UPaycag.png" /></figure><h3>Oligos</h3><p><strong>FWD:</strong> CACCGCAGCTTCGCGCAGGGGATGC</p><p><strong>REV:</strong> aaacGCATCCCCTGCGCGAAGCTGC</p><p><strong>Sequencing primer (U6–Genewiz):</strong> GACTATCATATGCTTACCGT</p><h3>Findings</h3><p>Assembly 1 targets CD19’s <strong>5′ UTR</strong>, the region before the protein coding sequence (CDS) in the selected CD19–201 transcript. A change here could affect how much CD19 is made, but it might also have little effect.</p><p>The predicted cut is at chr16:28,931,960 (hg38), on the minus strand (one of the two DNA strands) in exon 1 (the first segment retained in this RNA transcript). The PAM is TGG. Its on-target score is <strong>25.1*</strong> and its overall off-target score is <strong>69.8</strong>. Both are lower than Assembly 2’s, making Assembly 1 the weaker of those two guides on the reported predictions.</p><h3>Assembly 2</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Vvrft1Wj2cp5d6YGtZKzjw.png" /></figure><h3>Oligos</h3><p><strong>FWD:</strong> CACCGCATGGTGGTCAGACTCTCCG</p><p><strong>REV:</strong> aaacCGGAGAGTCTGACCACCATGC</p><p><strong>Sequencing primer (U6–Genewiz):</strong> GACTATCATATGCTTACCGT</p><h3>Findings</h3><p>Assembly 2 also targets the 5′ UTR in the selected CD19–201 transcript. Its predicted cut is at chr16:28,931,987 (hg38), on the minus strand in exon 1. The PAM is GGG.</p><p>Its on-target score is <strong>68.8*</strong> and its overall off-target score is <strong>80.3</strong>, the highest reported values among the three designs. These scores favour Assembly 2 over Assembly 1. Both target the 5′ UTR, though, so the higher scores don’t establish whether CD19 would be switched off.</p><h3>Assembly 3</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aMPDk4Iuf12fbrwkFL72gQ.png" /></figure><h3>Oligos</h3><p><strong>FWD:</strong> CACCGCCTGACTTCCATGGGGTG</p><p><strong>REV:</strong> aaacCACCCCATGGAAGTCAGGC</p><p><strong>Sequencing primer (U6–Genewiz):</strong> GACTATCATATGCTTACCGT</p><h3>Findings</h3><p>Assembly 3 targets CD19 at chr16:28,932,042 (hg38), on the minus strand. Its PAM is AGG. Based on the selected CD19–201 transcript annotation, this cut falls within exon 1’s <strong>protein-coding region</strong>.</p><p>Its on-target score is <strong>50.5*</strong>, between Assemblies 1 and 2. Its overall off-target score is <strong>58.3</strong>, the lowest reported value among the three guides. Its coding-region target adds a different trade-off to the comparison.</p><p>Targeting the coding region makes Assembly 3 more directly relevant to a possible CD19 knockout. Its guide sequence matches the 19-base insert in the plasmid design. A cut here could lead to DNA changes that disrupt CD19, depending on how the cell repairs it.</p><h3>Checks that mattered</h3><p>I checked Assembly 3’s 19-base insert against the original guide record after removing the CACC cloning overhang (extra bases for joining insert and plasmid). The sequences matched, confirming that the insert reflected the selected guide.</p><p>I also checked where each cut fell within the selected transcript. All three cuts are in exon 1, but only Assembly 3’s is in the coding region. Being in an exon doesn’t automatically mean a guide targets protein-coding DNA.</p><h3>What I learned and what comes next</h3><p>I learned to ask two separate questions: how well might a guide cut, and <strong>would a change at that location fit my goal?</strong> Assembly 1 gave me a starting point for comparing Assembly 2, but neither guide’s scores could tell me whether changing the 5′ UTR would disrupt CD19. With Assembly 3, I had to think about how repair in the coding region could affect the protein. I now have a clearer idea of what to check before choosing a guide.</p><p>If I did this again, I’d check the transcript annotation against my intended outcome before selecting guides. Next, I want to confirm the off-target scoring model and compare the guides using consistent settings. That would let me check whether the predicted specificity ranking holds. I’d also ask a researcher to review the design choices. Lab testing would be needed to measure cutting, unintended edits and changes in CD19 protein levels.</p><h3>Sources</h3><p><a href="https://help.benchling.com/hc/en-us/articles/37748593861133-Use-CRISPR-tools">Benchling (updated 2025). Use CRISPR tools. Benchling Help Center.</a></p><p><a href="https://www.addgene.org/guides/crispr/">Addgene (n.d.). CRISPR Guide. Addgene.</a></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/26516065/">Sotillo et al. (2015). Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery.</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=0d90cbf78908" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Do Cancer Cells Escape CAR T-Cell Therapy?]]></title>
            <link>https://medium.com/@junayd.alimohamed/how-do-cancer-cells-escape-car-t-cell-therapy-bfd54f37ef98?source=rss-d9ea5576040d------2</link>
            <guid isPermaLink="false">https://medium.com/p/bfd54f37ef98</guid>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[emerging-technology]]></category>
            <category><![CDATA[immunotherapy]]></category>
            <category><![CDATA[car-t-cell-therapy]]></category>
            <dc:creator><![CDATA[Junayd Alimohamed]]></dc:creator>
            <pubDate>Tue, 06 Oct 2026 04:30:44 GMT</pubDate>
            <atom:updated>2026-10-06T04:30:44.964Z</atom:updated>
            <content:encoded><![CDATA[<p>Imagine giving your own T-cells a power-up. Giving them a custom made puzzle piece that fits a specific antigen on a cancer cell. When they connect, it can trigger an attack from the immune system against the cancer. This treatment has revolutionized how certain cancers are treated!</p><p>But what happens when that specific antigen / marker disappears?</p><p>That’s the problem I’m exploring: <strong><em>Why do some cancer cells not respond or stop responding to CAR T-cell therapy?</em></strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*SvulvSdpe1tq82oJsiESdw.png" /><figcaption>Mechanism of action: The chimeric antigen receptor binds to the antigen CD19 on the cancer cell.</figcaption></figure><h4>Meet the Cells — and Their Target</h4><p>The purpose of the immune system is to recognize and destroy threats to the body. Cancer cells carry altered proteins which the immune system should recognize, however, these proteins or antigens are often hiding, thus helping the cancer cell to evade the immune response. There are many immune cells working together to try to uncover and remove cancer cells. A macrophage, a frontline fighter, can engulf abnormal cells and cellular debris. Macrophages will also release signalling proteins called cytokines, which act as an alarm and help coordinate an inflammatory response. During inflammation, blood vessels can widen and become more permeable, allowing more white blood cells to join.</p><p>Dendritic cells gather material from dead cancer cells and present fragments of their proteins at a nearby lymph node. It displays these antigen fragments via a protein called MHC. A T-cell in the lymph node can then recognize this displayed fragment from the cancer cell, and becomes activated, triggering a larger and more widespread immune response. Activated helper T-cells multiply and help coordinate the response, while activated cytotoxic — or killer — T-cells multiply and can kill cells displaying the matching antigen fragment.</p><p>Helper T-cells can also help activate B-cells, another type of immune cell, when they recognize a related antigen. These B-cells can multiply and develop into plasma cells, which produce large amounts of antibodies. The antibodies bind to their matching targets and can help other immune cells destroy them.</p><p>What happens when a cell that normally helps defend the body becomes part of the problem? <strong>B-cells can become cancerous</strong>, causing diseases such as B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia, and several types of lymphoma. Many of these cancerous B-cells still carry a surface protein called CD19, giving scientists a <strong>target</strong> they can engineer CAR T-cells to recognize. Here, I’ll focus on one example: targeting CD19 in B-ALL.</p><h4><strong>Engineering A Better Immune Response</strong></h4><p>So how is CAR T-cell therapy actually done? First, T-cells are collected from the patient’s blood. In the lab, scientists add genetic instructions that allow these cells to make a chimeric antigen receptor, or CAR. This is a specially designed protein on the T-cell’s surface that recognizes a chosen marker — for example CD19 — and sends signals inside the T-cell that can trigger an attack. The modified T-cells are grown into larger numbers in the lab and then infused back into the patient, where they can recognize and attack cells carrying that marker.</p><p>CAR T-cell therapy has given some patients with B-cell cancers another chance at remission, even when previous treatments haven’t worked.</p><h4>What Happens When the Target Disappears?</h4><p>The chimeric antigen receptor (CAR), like a 3D puzzle piece that looks for its matching surface marker on the cancerous B-cell. When that CAR T-cell finds its match, it binds and sends signals to activate the immune system, helping it multiply and attack. Suddenly, the cancer cell finds itself under attack. However, cancer cells can adapt and can lose or alter its matching marker. As a result, the CAR can no longer recognize its target. What happens next?</p><p>To find out, I’ll follow one target, <strong>CD19</strong> and explore how its absence can allow cancer cells to escape treatment. CD19 is a surface protein, or antigen, on many cancerous B-cells, including those in B-cell acute lymphoblastic leukemia (B-ALL). When this antigen disappears or changes in a way that prevents recognition, the CAR loses its recognizable target. I’ll examine research into this escape mechanism, what scientists found, and the limitations of their studies. Then I’ll explore whether recognizing a second target, CD22, could make escape harder — and why targeting two markers might still not solve the whole problem. But before exploring how this escape happens, we need to understand what CD19 is and why scientists choose to target it — even though healthy B-cells carry it too.</p><h4>Still Cancerous. No Longer Recognizable.</h4><p>For a CAR T-cell targeting CD19, the attack starts with finding the matching puzzle piece, or protein, on the surface of the B-cell. When its receptor binds to CD19 on the cancer cell, it sends signals inside the T-cell that can trigger an attack. Cancer cells are not identical. Some cancer cells already <strong>lack the CD19 protein</strong> <strong>before</strong> treatment begins. While the CAR T-cells attack the cells with the matching marker, those without it can survive and keep multiplying. Other cancer cells adapt: they lose or alter CD19 over time. This is called <strong>antigen escape</strong>, and this process allows cancer to return after treatment initially seemed to work. The cancer isn’t deliberately hiding — it’s the cells that escape recognition that get the chance to survive and grow. These routes are explored further in the<a href="https://www.nature.com/articles/s41467-021-21168-6"> pre-existing cell study</a> and<a href="https://pubmed.ncbi.nlm.nih.gov/26516065/"> research into altered CD19</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*1Iy19EnxPDuGFHOj5WVNUQ.png" /></figure><h4><strong>Quick Recap</strong></h4><ul><li>CD19 recognition is the trigger for the CAR T-cells to attack.</li><li>Some cancer cells already lack CD19 before treatment.</li><li>Others lose or alter the recognizable target.</li><li>Surviving cells can multiply and cause relapse.</li></ul><h4><strong>Was the Escape Route Already There?</strong></h4><p>In<a href="https://www.nature.com/articles/s41467-021-21168-6"> this study published in 2021</a>, researchers asked whether the leukemia cells that escaped CAR T treatment were already missing CD19 before treatment started. They examined leukemia samples from one patient with B-ALL before and after treatment, looking at gene activity in individual cells. They found rare cancer cells that already lacked CD19 before the CAR T-cells were given. When the cancer returned, it was CD19 negative, and their analysis supported the idea that those pre-existing cells had survived and multiplied. So sometimes, the escape route is already there before treatment even begins. But this was only one patient, which means the study can’t tell us how often this happens.</p><p>A larger study, the<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1709866"> ELIANA trial</a>, treated 75 children and young adults and reported 15 patients whose relapses included CD19 negative leukemia cells. Relapse means the cancer returns after responding to treatment. This data proved that CD19 negative relapses were common. However, this study was inconclusive as to if the cancer cells were already missing CD19 before treatment. Together, these findings show why relying on one marker as a a target can leave an opening for cancer to escape.</p><h4>Two Targets. Problem Solved?</h4><p>So what if the CAR T-cell had another target to look for? <strong>CD22</strong> is another protein found on B-cells, including many cancerous B-cells. The good news is, it can still be there when CD19 is absent. Scientists are exploring ways to engineer CAR T-cells to recognize CD19 or CD22, meaning either marker could trigger an attack. Think of it as giving them a second way to identify the same enemy. If the cancer cell loses CD19 but still carries enough recognizable CD22, losing that first target might no longer be enough to escape. A<a href="https://www.nature.com/articles/nm.4441"> CD22 targeting study</a> showed that CAR T-cells could produce remissions even in patients whose leukemia had little or no CD19. Remission means signs of cancer have decreased or disappeared; it doesn’t necessarily mean a cure. That gives researchers a reason to investigate using both targets together.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*khNDYYdXIz96qczsPjyMqw.png" /></figure><p>But adding another target doesn’t automatically fix the problem. In that CD22 study, relapses were associated with cancer cells displaying less CD22. The marker didn’t always need to disappear completely — there could be too little of it to trigger an effective attack. There’s also the question of how well the engineered receptor actually responds to each target. In a<a href="https://www.nature.com/articles/s41591-021-01436-0"> 2021 trial targeting both CD19 and CD22</a>, some cancers returned with little or no CD19 even though CD22 remained. Laboratory tests showed weaker responses to CD22 than to CD19, suggesting that the second targeting function wasn’t strong enough to fully close the escape route. These results highlight the many possible mechanisms of resistance which cancer cells may enact.</p><h4><strong>Quick Recap</strong></h4><ul><li>Recognizing CD19 <strong>or</strong> CD22 provides another route to attack.</li><li>CD22 could help when CD19 is missing.</li><li>Too little CD22 may allow cells to escape.</li><li>The second targeting function must trigger an effective response.</li></ul><h4>A Backup Target Has to Deliver</h4><p>My take is that CAR T-cell therapy is an impressive treatment, but the escape mechanisms I’ve explored show that there’s still room to improve this treatment. Adding a second target like CD22 could make escape harder, but the second target needs to be more than a backup player. It has to trigger an effective response when the first target is gone. These studies give us reasons to keep investigating, but they don’t prove that dual targeting will prevent relapse or work better for every patient. The next question I want to explore is: how can scientists make the CD22 response strong enough to attack cancer cells even when they display very little of the marker?</p><p>That also makes me wonder what other approaches could help.<a href="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy"> Chemotherapy is already commonly given before CAR T-cell therapy</a> to help prepare the immune environment. Could a different combination or treatment sequence help destroy cancer cells that CAR T-cells miss? Another question is whether a drug could prevent cancer cells from losing CD19, or restore a recognizable version of it on their surface. These are possibilities to investigate, rather than solutions we can assume will work. I would want to know whether they could reduce relapse without adding too much harm to healthy cells.</p><h4>Key Takeaways</h4><ul><li>CAR T-cells use engineered receptors to recognize specific markers on cells.</li><li>Cancer cells can escape by losing or altering the targeted marker.</li><li>Some cancer cells already lack CD19 before treatment begins.</li><li>Targeting CD19 or CD22 could help attack cells missing one marker.</li><li>Low marker levels or weak CAR responses can still allow escape.</li><li>Early remission does not guarantee cancer will stay away.</li><li>Dual targeting is promising, but preventing relapse requires stronger evidence.</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bfd54f37ef98" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>